Analyst Corinne Johnson from Goldman Sachs maintained a Buy rating on Roivant Sciences and increased the price target to $38.00 from $33.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Corinne Johnson’s rating is based on the significant value unlocked by Roivant’s settlement related to its lipid nanoparticle intellectual property and the clarity it brings to a previously binary legal overhang. The expected majority share of the settlement proceeds, combined with a relatively modest tax burden, meaningfully strengthens the balance sheet and supports both internal pipeline investment and an expanded share repurchase program.
Corinne Johnson has given his Buy rating due to a combination of factors, including a clearer investment case ahead of key clinical and regulatory milestones such as the planned U.S. launch of brepocitinib. In addition, the possibility of further cash inflows from ongoing patent actions against other COVID vaccine manufacturers and a DCF-derived price target of $38, based on conservative assumptions for risk and long-term growth, provides further justification for a positive stance despite acknowledged clinical, competitive, and execution risks.
In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $34.00 price target.
ROIV’s price has also changed dramatically for the past six months – from $12.590 to $27.850, which is a 121.21% increase.